logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Crizotinib for paediatric ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour

< Back

Crizotinib for paediatric ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour

Drugs

Cancer and Palliative Care

March 2021


Anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumour (IMT) are both rare conditions that usually affect children and young adults. ALCL is a type of cancer that occurs when T-cells, which contribute to the body’s immune system, become abnormal. IMTs are most commonly non-cancerous (benign), however in some cases the tumour can become cancerous (malignant). Both conditions can be ALK-positive (ALK+), this means that the tumour cells have a mutation in anaplastic lymphoma kinase (ALK) resulting in uncontrolled cell replication. These conditions may not be able to be treated through surgical removal of the tumour (unresectable); they may also come back after treatment (relapse) or be resistant to current treatment options (refractory).

Crizotinib is an anticancer medication that can be taken up to twice daily, orally, as a capsule. This medication acts by blocking the growth and spread of tumorous cells that are ALK+. If licenced, crizotinib would be the first biomarker-driven therapy for paediatric ALK+ ALCL and IMT.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts